Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 73

  • 956 clinical trials
  • 391 recruiting
  • 345 conditions
  • 28 countries

Conditions in this area

345 conditions with trials, the busiest first

Breast cancer168Prostate cancer101Ovarian cancer91Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer41Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer18Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+321

Clinical trials in Reproductive system and breast disorders

956 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

956 clinical trials

Infertility male

Not recruiting
Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Follitropin Delta
  • Sponsor:Ferring Pharmaceuticals A/S

Dysmenorrhoea

Not recruiting
Registered drug
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Dry Extract From Chaste Tree Fruits (7-11:1), Extraction Solvent: Ethanol 70% (V/V)
  • Sponsor:Bionorica SE

Triple negative breast cancer

Not recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Metformin Hydrochloride
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Endometrial cancer+1

Not recruiting
Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pemigatinib
  • Sponsor:Incyte Corp.

Hormone receptor positive breast cancer+1

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:ETOP IBCSG Partners Foundation

Hormone-refractory prostate cancer

Not recruiting
Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Novartis Pharma AG

Cervix carcinoma

Not recruiting
Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Brimonidine Tartrate
  • Sponsor:Seagen Inc.

Breast cancer

Not recruiting
InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Breast cancer+3

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:WSG Women's Cancer Study Group GmbH

Breast cancer metastatic

Not recruiting
Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Elacestrant
  • Sponsor:Stemline Therapeutics Inc.

Hormone receptor positive HER2 negative breast cancer

Not recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Solti Group

Endometrial cancer

Not recruiting
Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab77 clinical trialsLetrozole73 clinical trialsFulvestrant58 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane46 clinical trialsAnastrozole44 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.